三联疗法Breztri Aerosphere显著降低中重度COPD急性发作率

2020-06-25 Allan MedSci原创

III期临床试验(ETHOS研究)表明,与双联疗法相比,阿斯利康的三联疗法Breztri Aerosphere(布地奈德/吡喃糖/富马酸福莫特罗)显著降低了慢性阻塞性肺疾病(COPD)的急性发作率。

III期临床试验(ETHOS研究)表明,与双联疗法相比,阿斯利康的三联疗法Breztri Aerosphere(布地奈德/吡喃糖/富马酸福莫特罗)显著降低了慢性阻塞性肺疾病(COPD)的急性发作率。

与Bevespi Aerosphere(吡喃糖/富马酸福莫特罗)相比,Breztri Aerosphere组患者的急性发作率减少了24%(p <0.001)。与PT009(布地奈德/富马酸福莫特罗)相比,Breztri Aerosphere组患者的急性发作率减少13%(p = 0.003)。在关键次要终点中,与Bevespi Aerosphere相比,Breztri Aerosphere组患者的全因死亡率降低了46%(p = 0.01)。

该研究结果近日发表在《新英格兰医学杂志》上,并同时在美国胸科学会虚拟研讨会上发表。阿斯利康将继续与卫生当局一起审查这些数据。ETHOS试验的首席研究员Klaus Rabe表示:“ETHOS试验证明了Breztri Aerosphere在降低COPD恶化率方面的益处。研究结果还表明,降低全因死亡率的风险是可以实现的”。

 

原始出处:

https://www.firstwordpharma.com/node/1735392?tsid=4

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1779382, encodeId=4e171e7938247, content=<a href='/topic/show?id=2e6a2053ab' target=_blank style='color:#2F92EE;'>#Aerosphere#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2053, encryptionId=2e6a2053ab, topicName=Aerosphere)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6779163, createdName=liuhuangbo, createdTime=Thu Apr 29 07:37:10 CST 2021, time=2021-04-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1364612, encodeId=00f41364612fe, content=<a href='/topic/show?id=7c5615628ad' target=_blank style='color:#2F92EE;'>#ROS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15628, encryptionId=7c5615628ad, topicName=ROS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=acc3210, createdName=lsndxfj, createdTime=Sat Jun 27 09:37:10 CST 2020, time=2020-06-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1554325, encodeId=ad231554325cf, content=<a href='/topic/show?id=8402522319e' target=_blank style='color:#2F92EE;'>#急性发作#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=52231, encryptionId=8402522319e, topicName=急性发作)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=287314518946, createdName=anminleiryan, createdTime=Sat Jun 27 09:37:10 CST 2020, time=2020-06-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1613730, encodeId=96081613e30ac, content=<a href='/topic/show?id=a59419e9059' target=_blank style='color:#2F92EE;'>#三联疗法#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=19790, encryptionId=a59419e9059, topicName=三联疗法)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552519418574, createdName=12498636m55(暂无昵称), createdTime=Sat Jun 27 09:37:10 CST 2020, time=2020-06-27, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1779382, encodeId=4e171e7938247, content=<a href='/topic/show?id=2e6a2053ab' target=_blank style='color:#2F92EE;'>#Aerosphere#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2053, encryptionId=2e6a2053ab, topicName=Aerosphere)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6779163, createdName=liuhuangbo, createdTime=Thu Apr 29 07:37:10 CST 2021, time=2021-04-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1364612, encodeId=00f41364612fe, content=<a href='/topic/show?id=7c5615628ad' target=_blank style='color:#2F92EE;'>#ROS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15628, encryptionId=7c5615628ad, topicName=ROS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=acc3210, createdName=lsndxfj, createdTime=Sat Jun 27 09:37:10 CST 2020, time=2020-06-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1554325, encodeId=ad231554325cf, content=<a href='/topic/show?id=8402522319e' target=_blank style='color:#2F92EE;'>#急性发作#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=52231, encryptionId=8402522319e, topicName=急性发作)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=287314518946, createdName=anminleiryan, createdTime=Sat Jun 27 09:37:10 CST 2020, time=2020-06-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1613730, encodeId=96081613e30ac, content=<a href='/topic/show?id=a59419e9059' target=_blank style='color:#2F92EE;'>#三联疗法#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=19790, encryptionId=a59419e9059, topicName=三联疗法)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552519418574, createdName=12498636m55(暂无昵称), createdTime=Sat Jun 27 09:37:10 CST 2020, time=2020-06-27, status=1, ipAttribution=)]
    2020-06-27 lsndxfj
  3. [GetPortalCommentsPageByObjectIdResponse(id=1779382, encodeId=4e171e7938247, content=<a href='/topic/show?id=2e6a2053ab' target=_blank style='color:#2F92EE;'>#Aerosphere#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2053, encryptionId=2e6a2053ab, topicName=Aerosphere)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6779163, createdName=liuhuangbo, createdTime=Thu Apr 29 07:37:10 CST 2021, time=2021-04-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1364612, encodeId=00f41364612fe, content=<a href='/topic/show?id=7c5615628ad' target=_blank style='color:#2F92EE;'>#ROS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15628, encryptionId=7c5615628ad, topicName=ROS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=acc3210, createdName=lsndxfj, createdTime=Sat Jun 27 09:37:10 CST 2020, time=2020-06-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1554325, encodeId=ad231554325cf, content=<a href='/topic/show?id=8402522319e' target=_blank style='color:#2F92EE;'>#急性发作#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=52231, encryptionId=8402522319e, topicName=急性发作)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=287314518946, createdName=anminleiryan, createdTime=Sat Jun 27 09:37:10 CST 2020, time=2020-06-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1613730, encodeId=96081613e30ac, content=<a href='/topic/show?id=a59419e9059' target=_blank style='color:#2F92EE;'>#三联疗法#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=19790, encryptionId=a59419e9059, topicName=三联疗法)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552519418574, createdName=12498636m55(暂无昵称), createdTime=Sat Jun 27 09:37:10 CST 2020, time=2020-06-27, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1779382, encodeId=4e171e7938247, content=<a href='/topic/show?id=2e6a2053ab' target=_blank style='color:#2F92EE;'>#Aerosphere#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2053, encryptionId=2e6a2053ab, topicName=Aerosphere)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6779163, createdName=liuhuangbo, createdTime=Thu Apr 29 07:37:10 CST 2021, time=2021-04-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1364612, encodeId=00f41364612fe, content=<a href='/topic/show?id=7c5615628ad' target=_blank style='color:#2F92EE;'>#ROS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15628, encryptionId=7c5615628ad, topicName=ROS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=acc3210, createdName=lsndxfj, createdTime=Sat Jun 27 09:37:10 CST 2020, time=2020-06-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1554325, encodeId=ad231554325cf, content=<a href='/topic/show?id=8402522319e' target=_blank style='color:#2F92EE;'>#急性发作#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=52231, encryptionId=8402522319e, topicName=急性发作)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=287314518946, createdName=anminleiryan, createdTime=Sat Jun 27 09:37:10 CST 2020, time=2020-06-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1613730, encodeId=96081613e30ac, content=<a href='/topic/show?id=a59419e9059' target=_blank style='color:#2F92EE;'>#三联疗法#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=19790, encryptionId=a59419e9059, topicName=三联疗法)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552519418574, createdName=12498636m55(暂无昵称), createdTime=Sat Jun 27 09:37:10 CST 2020, time=2020-06-27, status=1, ipAttribution=)]

相关资讯

Eur Respir J:环境真菌致敏与COPD患者较差的临床预后有关

真菌致敏在COPD患者中普遍存在,并伴有COPD恶化频繁发作,代表潜在的可治疗特性。室外和室内(家庭)环境是COPD患者真菌过敏原暴露的主要场所。

JAMA:肺气道发育水平影响老年人群COPD风险

在老年人中,气道发育不协调与COPD风险显著相关,相对于肺部,气道树径越小,COPD风险越大

NEJM:含布地奈德的三联方案可有效控制中重度COPD进展

在格隆溴铵+沙美特罗基础上,每日2次,含布地奈德的三联治疗方案可更有效的控制中重度COPD疾病进展

Respir Res:中性粒细胞弹性蛋白酶作为COPD中细菌感染的生物标记物

慢性阻塞性肺病(COPD)主要与嗜中性粒细胞炎症有关。活性中性粒细胞弹性蛋白酶(NE)是一种丝氨酸蛋白酶,由中性粒细胞分泌,以应对炎症和病原体入侵。本研究旨在探究NE是否可以作为COPD患者的细菌感染

JAMA:极早进行肺康复治疗可降低慢性阻塞性肺病恶化患者死亡风险

研究认为,对于慢性阻塞性肺病恶化患者,在出院后3个月内开始肺康复与1年死亡率的降低显著相关

Chest:血清IgG水平和COPD住院风险

低丙种球蛋白血症与较高的COPD住院风险有关。

拓展阅读

J Ethnopharmacol:结合网络药理学和药理学研究探讨定喘汤抗慢性阻塞性肺疾病的潜在机制

探讨定喘汤(DCT)在体内和体外治疗慢性阻塞性肺疾病(COPD)的疗效,并阐明其抗COPD的可能机制。

走出COPD新药研发“死亡谷”:赛诺菲解锁炎症性疾病新“地图”

作为COPD领域即将迎来的第一款生物制剂,度普利尤单抗也即将开创COPD治疗新纪元,为仅有“对症治疗”方法的患者提供全新的治疗选择。从特应性皮炎到COPD,度普利尤单抗的临床价值被充分挖掘。

通过无创通气降低 PCO2 与改善慢性高碳酸血症呼吸衰竭患者的生存率相关

接受无创通气治疗的慢性高碳酸血症受试者的 PCO2 相对基线的降低与生存率的提高相关。管理策略应以最大程度地减少 PCO2 为目标。

Academic radiology:CT放射组学特征在慢性阻塞性肺病患者中的应用

基于纹理的放射组学特征可以从CT图像中提取的定量特征,为临床提供关于体素灰度的相关信息。

过多的氧气对COPD患者不利?

人体的重要器官在低氧环境下是难以承受的,而这种治疗策略(即因担心二氧化碳浓度升高而不给慢性阻塞性肺病患者吸氧)对患者来说基本上是致命的,对被误导的医生来说则是职业生涯的悲剧。

Front Immunol:综合代谢组学和脂质组学特征辨证慢性阻塞性肺疾病的中医证型

结合代谢组学和脂质组学,表征健康受试者与COPD不同中医证型的代谢标志物。